We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Immunoprofiling HTLV-1 Blood Samples Show Altered Innate Cell Responsiveness

By LabMedica International staff writers
Posted on 09 Dec 2021
Print article
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Bioscience)
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Bioscience)
The Human T-cell Leukemia Virus-1 (HTLV-1)-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is a progressive neurodegenerative disease characterized by the demyelination of the middle-to-lower thoracic cord.

HTLV-1 targets mainly T-cells, altering their function and ability to induce an antiviral specific immune response, even participating in the disease evolution as mentioned previously. However, in addition to T-cells, HTLV-1 also targets innate immune cells such as classical and plasmacytoid dendritic cells (cDCs and pDCs, respectively), as well as monocytes.

Medical Virologists at the Université Claude Bernard Lyon 1 (Lyon, France) and their colleagues analyzed innate cell responses at steady state and after blood cell stimulation using an agonist of the toll-like receptor (TLR)7/8-signaling pathway in blood samples from a Brazilian cohort (15 HAM/TSP patients, 15 HTLV-1 asymptomatic carriers, and 15 non-infected individuals). The average age was 52 ±6.35 years for men and 49.15 ±10.84 years for women. Age means were 49.8 years for healthy donors (HD), 46.93 years for asymptomatic carriers (AC) and 53.8 years for HAM/TSP.

HTLV-1 serologic diagnosis was made by ELISA (Ortho Diagnostics, Rochester, NY, USA) and positive samples were confirmed by western blot. All patients whose serum sample was reactive with either test was submitted to a nested-PCR using HTLV-1 generic primers and amplified products were digested with restriction enzymes. Blood samples were processed, stimulated and analyzed with a LSR Fortessa X-20 cytometer (BD Biosciences, San Jose, CA, USA). Fluorochrome compensation was performed with BD Biosciences’ compensation beads and FMO (Fluorescence Minus One) conditions.

The investigators observed a lower response of IFNα+ DCs and monocytes in HAM/TSP compared to asymptomatic carriers, as a potential consequence of corticosteroid treatments. In contrast, a higher frequency of monocytes producing MIP-1α and pDC producing IL-12 was detected in HAM/TSP blood samples, together with higher IFNγ responsiveness of NK cells, suggesting an increase sensitivity to inflammatory response in HAM/TSP patients compared to asymptomatic carriers. This sustained inflammatory responsiveness could be linked or be at the origin of the neuroinflammatory status in HAM/TSP patients.

The authors concluded that their findings suggest an impaired antiviral response and increased inflammatory responsiveness by dendritic cells and monocytes in HAM/TSP patients compared to asymptomatic carriers. This sustained inflammatory responsiveness upon innate cell activation could participate in the establishment of the HAM/TSP disease. The study was published on November 12, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Université Claude Bernard Lyon 1
Ortho Diagnostics
BD Bioscience


Gold Supplier
Clinical Chemistry Reagents
SEKURE Clinical Chemistry Reagents
New
Benchtop Centrifuge & Vortexer
ExiSpin
New
Silver Supplier
Anti-Müllerian Hormone (AMH) ELISA Test
PCOCheck ELISA (CE)
New
Gold Supplier
NT-proBNP Quantitative Antigen Test
NT-proBNP-CHECK-1

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.